We are live on ! Find out more
TNDM icon

Tandem Diabetes Care

63 hedge funds and large institutions have $14.7M invested in Tandem Diabetes Care in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% less ownership

Funds ownership: 4.69%3.69% (-1%)

19% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 21

21% less funds holding

Funds holding: 8063 (-17)

47% less capital invested

Capital invested by funds: $27.8M → $14.7M (-$13.1M)

57% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 28

Holders
63
Holders Change
-17
Holders Change %
-21.25%
% of All Funds
1.57%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
17
Reduced
21
Closed
28
Calls
$34K
Puts
Net Calls
+$34K
Net Calls Change
+$34K

TNDM Hedge Fund Activity: Q2 2017 in Review

63 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q2 2017, worth a combined $14.7M — down 47% from $27.8M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of TNDM and 12 opened new positions — a net loss of 16 holders — while 21 trimmed existing stakes and 17 added.

The largest buyer was Russell Investments Group, adding an estimated $259K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.92M sold.

  • 63 institutional investors held Tandem Diabetes Care (TNDM) as of Q2 2017, down from 80 in Q1 2017.
  • Funds reported $14.7M of Tandem Diabetes Care stock for Q2 2017, down 47% quarter-over-quarter.
  • 12 funds opened new Tandem Diabetes Care positions in Q2 2017 and 28 closed out, a net change of -16 holders.
  • The largest Tandem Diabetes Care buyer in Q2 2017 was Russell Investments Group, an estimated $259K added.
  • The largest Tandem Diabetes Care seller in Q2 2017 was Alyeska Investment Group, an estimated $1.92M sold.

Based on aggregated 13F filings for Q2 2017.